Directly observed treatment, short-course

Directly Observed Treatment, Short-Course (DOTS)

Directly Observed Treatment, Short-Course (DOTS) is a comprehensive strategy for the detection and treatment of tuberculosis (TB). It was developed by the World Health Organization (WHO) in the early 1990s to address the global TB epidemic. DOTS is designed to ensure that patients adhere to their treatment regimens, thereby reducing the risk of drug resistance and improving treatment outcomes.

Overview

DOTS is based on five key components:

1. Political Commitment: Strong government support and sustained financing are crucial for the successful implementation of DOTS programs. This includes the establishment of national TB control programs and policies that prioritize TB treatment and prevention.

2. Case Detection through Quality-Assured Bacteriology: Accurate diagnosis of TB is essential. DOTS relies on sputum smear microscopy, a cost-effective and reliable method for detecting TB bacteria in patients.

3. Standardized Treatment Regimen: DOTS prescribes a standardized treatment regimen of first-line anti-TB drugs, typically lasting six to eight months. The regimen includes a combination of drugs such as isoniazid, rifampicin, pyrazinamide, and ethambutol.

4. Directly Observed Therapy: A healthcare worker or trained volunteer directly observes patients as they take their medication. This ensures adherence to the treatment regimen and helps prevent the development of drug-resistant TB strains.

5. Effective Drug Supply and Management: A reliable supply of quality-assured anti-TB drugs is essential. DOTS programs must have efficient drug procurement and distribution systems to prevent stockouts and ensure that patients receive the full course of treatment.

Impact and Challenges

DOTS has been instrumental in reducing TB incidence and mortality worldwide. It has been credited with saving millions of lives and is considered one of the most cost-effective health interventions. However, challenges remain, including the emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), which require more complex and costly treatment regimens.

Implementation

DOTS has been implemented in over 180 countries, with varying degrees of success. The strategy has been adapted to local contexts, taking into account factors such as healthcare infrastructure, cultural practices, and the prevalence of HIV/AIDS, which can complicate TB treatment.

Also see

• Tuberculosis
• Multidrug-resistant tuberculosis
• World Health Organization
• Public health
• Infectious disease control